Press Releases Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 Oct 09, 2026 Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes Oct 06, 2026 Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes Oct 05, 2026 Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes Oct 05, 2026 Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate Oct 04, 2026 Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate Sep 03, 2026 Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Aug 27, 2026 Vaxcyte to Participate in Upcoming Investor Conferences Aug 05, 2026 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Jul 08, 2026 Vaxcyte to Participate in Upcoming Investor Conferences Jun 02, 2026 Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 Oct 09, 2026 Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes Oct 06, 2026 Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes Oct 05, 2026 Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes Oct 05, 2026 Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate Oct 04, 2026 Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate Sep 03, 2026 Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Aug 27, 2026 Vaxcyte to Participate in Upcoming Investor Conferences Aug 05, 2026 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Jul 08, 2026 Vaxcyte to Participate in Upcoming Investor Conferences Jun 02, 2026 Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
